Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51


Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.

Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B, O'Leary B, Herrera-Abreu MT, Cutts RJ, Garcia-Murillas I, Bye H, Walker BA, Gonzalez De Castro D, Yuan L, Jamal S, Hubank M, Lopez-Knowles E, Schuster EF, Dowsett M, Osin P, Nerurkar A, Parton M, Okines AFC, Johnston SRD, Ring A, Turner NC.

Clin Cancer Res. 2020 Feb 1;26(3):608-622. doi: 10.1158/1078-0432.CCR-18-4044. Epub 2019 Oct 7.


Complete excision with narrow margins provides equivalent local control to wider excision in breast conservation for invasive cancer.

Tang SSK, Rapisarda F, Nerurkar A, Osin P, MacNeill F, Smith I, Johnston S, Ross G, Mohammed K, Gui GPH.

BJS Open. 2018 Dec 12;3(2):161-168. doi: 10.1002/bjs5.50121. eCollection 2019 Apr.


INTEND II randomized clinical trial of intraoperative duct endoscopy in pathological nipple discharge.

Gui G, Agusti A, Twelves D, Tang S, Kabir M, Montgomery C, Nerurkar A, Osin P, Isacke C.

Br J Surg. 2018 Nov;105(12):1583-1590. doi: 10.1002/bjs.10990. Epub 2018 Sep 20.


Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC.

Sci Transl Med. 2015 Nov 11;7(313):313ra182. doi: 10.1126/scitranslmed.aac7551.


Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC.

Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.


Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.

López-Knowles E, Wilkerson PM, Ribas R, Anderson H, Mackay A, Ghazoui Z, Rani A, Osin P, Nerurkar A, Renshaw L, Larionov A, Miller WR, Dixon JM, Reis-Filho JS, Dunbier AK, Martin LA, Dowsett M.

Breast Cancer Res. 2015 Mar 11;17:35. doi: 10.1186/s13058-015-0532-0.


The radiological excision of high risk and malignant lesions using the INTACT breast lesion excision system. A case series with an imaging follow up of at least 5 years.

Allen SD, Osin P, Nerurkar A.

Eur J Surg Oncol. 2014 Jul;40(7):824-9. doi: 10.1016/j.ejso.2014.03.022. Epub 2014 Apr 2.


DNA promoter hypermethylation profiles in breast duct fluid.

Twelves D, Nerurkar A, Osin P, Dexter T, Ward A, Gui GP, Isacke CM.

Breast Cancer Res Treat. 2013 Jun;139(2):341-50. doi: 10.1007/s10549-013-2544-8. Epub 2013 May 15.


Noninvasive detection of HER2 amplification with plasma DNA digital PCR.

Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A, Turner NC.

Clin Cancer Res. 2013 Jun 15;19(12):3276-84. doi: 10.1158/1078-0432.CCR-12-3768. Epub 2013 May 1.


Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.

Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, A'hern R, Miller WR, Smith IE, Dowsett M.

Clin Cancer Res. 2013 May 15;19(10):2775-86. doi: 10.1158/1078-0432.CCR-12-1000. Epub 2013 Mar 14.


The feasibility of nipple aspiration and duct lavage to evaluate the breast duct epithelium of women with increased breast cancer risk.

Twelves D, Nerurkar A, Osin P, Ward A, Isacke CM, Gui GP.

Eur J Cancer. 2013 Jan;49(1):65-71. doi: 10.1016/j.ejca.2012.07.012. Epub 2012 Aug 21.


The anatomy of fluid-yielding ducts in breast cancer.

Twelves D, Nerurkar A, Osin P, Ward A, Isacke CM, Gui GP.

Breast Cancer Res Treat. 2012 Apr;132(2):555-64. doi: 10.1007/s10549-011-1623-y. Epub 2011 Jun 15.


Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.

Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'hern R, Nerurkar A, Osin P, Smith IE, Dowsett M.

Breast Cancer Res. 2010;12(5):R76. doi: 10.1186/bcr2719. Epub 2010 Sep 28.


Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA; UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology.

Br J Cancer. 2010 Sep 7;103(6):918-24. doi: 10.1038/sj.bjc.6605822. Epub 2010 Aug 24.


Metastatic breast cancer presenting as a primary hindgut neuroendocrine tumour.

Okines AF, Hawkes EA, Rao S, VAN As N, Marsh H, Riddell A, Wilson PO, Osin P, Wotherspoon AC.

Anticancer Res. 2010 Jul;30(7):3015-8. Erratum in: Anticancer Res. 2011 Apr;31(4):1513. Wetherspoon, Andrew C [corrected to Wotherspoon, Andrew C].


Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.

Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, Parker JS, Perou CM, Ellis MJ, Dowsett M.

J Clin Oncol. 2010 Mar 1;28(7):1161-7. doi: 10.1200/JCO.2009.23.9616. Epub 2010 Feb 1.


Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M.

Ann Oncol. 2009 Dec;20(12):1948-52. doi: 10.1093/annonc/mdp234. Epub 2009 Jul 1.


Malignant myoepithelioma arising in adenomyoepithelioma of the breast and coincident multiple gastrointestinal stromal tumours in a patient with neurofibromatosis type 1.

Hegyi L, Thway K, Newton R, Osin P, Nerurkar A, Hayes AJ, Fisher C.

J Clin Pathol. 2009 Jul;62(7):653-5. doi: 10.1136/jcp.2008.063628.


Testing the feasibility of intra-operative sentinel lymph node touch imprint cytology.

Hamidian Jahromi A, Narayanan S, MacNeill F, Osin P, Nerurkar A, Gui G.

Ann R Coll Surg Engl. 2009 May;91(4):336-9. doi: 10.1308/003588409X391758. Epub 2009 Apr 2.


Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls.

Locke I, Kote-Jarai Z, Fackler MJ, Bancroft E, Osin P, Nerurkar A, Izatt L, Pichert G, Gui GP, Eeles RA.

Breast Cancer Res. 2007;9(1):R20.


Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls.

Locke I, Kote-Jarai Z, Bancroft E, Bullock S, Jugurnauth S, Osin P, Nerurkar A, Izatt L, Pichert G, Gui GP, Eeles RA.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1399-402.


Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer.

Gui GP, Joubert DJ, Reichert R, Ward A, Lakhani S, Osin P, Nerurkar A, A'Hern R, Benson K, Underwood SR.

Eur J Surg Oncol. 2005 Sep;31(7):707-14.


The inframammary fold: contents, clinical significance and implications for immediate breast reconstruction.

Gui GP, Behranwala KA, Abdullah N, Seet J, Osin P, Nerurkar A, Lakhani SR.

Br J Plast Surg. 2004 Mar;57(2):146-9.


Abolish C3.

Osin P.

Cytopathology. 2004 Feb;15(1):64. No abstract available.


The diagnosis and management of pre-invasive breast disease: the role of new diagnostic techniques.

Nerurkar A, Osin P.

Breast Cancer Res. 2003;5(6):305-8. Epub 2003 Oct 9. Review.


Distinct genetic and epigenetic changes in medullary breast cancer.

Osin P, Lu YJ, Stone J, Crook T, Houlston RS, Gasco M, Gusterson BA, Shipley J.

Int J Surg Pathol. 2003 Jul;11(3):153-8.


Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.

Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA; Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators; British Association of Urological Surgeons Section of Oncology.

Am J Hum Genet. 2003 Jan;72(1):1-12. Epub 2002 Dec 9.


The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF.

J Clin Oncol. 2002 May 1;20(9):2310-8.


E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia.

Brooks LA, Sullivan A, O'Nions J, Bell A, Dunne B, Tidy JA, Evans DJ, Osin P, Vousden KH, Gusterson B, Farrell PJ, Storey A, Gasco M, Sakai T, Crook T.

Br J Cancer. 2002 Jan 21;86(2):263-8.


Concomitant inactivation of p53 and Chk2 in breast cancer.

Sullivan A, Yuille M, Repellin C, Reddy A, Reelfs O, Bell A, Dunne B, Gusterson BA, Osin P, Farrell PJ, Yulug I, Evans A, Ozcelik T, Gasco M, Crook T.

Oncogene. 2002 Feb 21;21(9):1316-24.


The pathology of familial breast cancer: Immunohistochemistry and molecular analysis.

Osin PP, Lakhani SR.

Breast Cancer Res. 1999;1(1):36-40. Epub 1999 Oct 27. Review.


The basic pathology of human breast cancer.

Mallon E, Osin P, Nasiri N, Blain I, Howard B, Gusterson B.

J Mammary Gland Biol Neoplasia. 2000 Apr;5(2):139-63. Review.


BCL10 is rarely mutated in human prostate carcinoma, small-cell lung cancer, head and neck tumours, renal carcinoma and sarcomas. MPT Collaborators, St George's Hospital Collaborators.

Gill S, Broni J, Jefferies S, Osin P, Kovacs G, Maitland NJ, Eeles R, Edwards SM, Dyer MJ, Willis TG, Cooper CS.

Br J Cancer. 1999 Jul;80(10):1565-8.


Synovial sarcoma specific translocation associated with both epithelial and spindle cell components.

Birdsall S, Osin P, Lu YJ, Fisher C, Shipley J.

Int J Cancer. 1999 Aug 12;82(4):605-8.


Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.

Smith PD, Crossland S, Parker G, Osin P, Brooks L, Waller J, Philp E, Crompton MR, Gusterson BA, Allday MJ, Crook T.

Oncogene. 1999 Apr 15;18(15):2451-9.


Establishing germ cell origin of undifferentiated tumors by identifying gain of 12p material using comparative genomic hybridization analysis of paraffin-embedded samples.

Summersgill B, Goker H, Osin P, Huddart R, Horwich A, Fisher C, Shipley J.

Diagn Mol Pathol. 1998 Oct;7(5):260-6.


Experimental pathology and breast cancer genetics: new technologies.

Osin P, Shipley J, Lu YJ, Crook T, Gusterson BA.

Recent Results Cancer Res. 1998;152:35-48. Review.


Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers.

Osin P, Gusterson BA, Philp E, Waller J, Bartek J, Peto J, Crook T.

Eur J Cancer. 1998 Oct;34(11):1683-6.


p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.

Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA.

Oncogene. 1998 Oct 1;17(13):1681-9.


Breast development gives insights into breast disease.

Osin PP, Anbazhagan R, Bartkova J, Nathan B, Gusterson BA.

Histopathology. 1998 Sep;33(3):275-83.


Accidental isopropyl alcohol enema leading to coma and death.

Haviv YS, Safadi R, Osin P.

Am J Gastroenterol. 1998 May;93(5):850-1. No abstract available.


Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.

Osin P, Crook T, Powles T, Peto J, Gusterson B.

Lancet. 1998 May 16;351(9114):1487. No abstract available.


The development of epithelial phenotypes in the human fetal and infant breast.

Anbazhagan R, Osin PP, Bartkova J, Nathan B, Lane EB, Gusterson BA.

J Pathol. 1998 Feb;184(2):197-206.


p53 mutations in BRCA1-associated familial breast cancer.

Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA.

Lancet. 1997 Aug 30;350(9078):638-9. No abstract available.


Hemangioendothelioma of the temporal bone in a child.

Eliashar R, Saah D, Osin P, Sichel JY.

Int J Pediatr Otorhinolaryngol. 1997 May 4;40(1):67-71.


Fibrosarcoma of the thyroid in a man exposed to fallout from the Chernobyl accident.

Sichel JY, Wygoda M, Dano I, Osin P, Elidan J.

Ann Otol Rhinol Laryngol. 1996 Oct;105(10):832-4.


Supplemental Content

Support Center